Success Metrics

Active Trials
9(90%)

Phase Distribution

Ph phase_1
1
10%
Ph phase_3
2
20%
Ph phase_2
6
60%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

10

all time

Status Distribution
Active(9)
Other(1)

Detailed Status

Recruiting8
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 32 (22.2%)

Trials by Status

unknown110%
recruiting880%
active_not_recruiting110%

Recent Activity

9 active trials
Showing 5 of 10
recruitingphase_2

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

NCT07276386
recruitingphase_2

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

NCT07057596
recruitingphase_3

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149
recruitingphase_2

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
recruitingphase_3

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07276386Phase 2

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Recruiting
NCT07057596Phase 2

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

Recruiting
NCT06246149Phase 3

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Recruiting
NCT06070012Phase 2

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Recruiting
NCT05549297Phase 3

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Recruiting
NCT06627244Phase 2

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Recruiting
NCT06942442Phase 2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Recruiting
NCT05315258Phase 2

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Active Not Recruiting
NCT05785754Phase 1

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting
NCT04960891

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10